TVM UK is pleased to announce the launch of Vetbromide, the latest addition to its Epilepsy Range which already includes Soliphen and Ziapam.
Vetbromide is the only potassium bromide formulation licensed for both adjunct and monotherapy indications in dogs with idiopathic epilepsy.
Presented as a 600mg double divisible tablet, Vetbromide is convenient for both large and small dogs, and allows greater flexibility with dose titration. Tablets are also blister packed for ease of storage and dispensing, with a four-year unopened shelf life.
Alongside the launch, TVM UK is providing a suite of supporting materials to include:
- Product guidelines
- Treatment and monitoring guidelines
- Seizure management “lunch and learn” sessions
- Pet owner information
To support the launch of Vetbromide, TVM UK has also created a free e-Learning tool which takes veterinary staff through the process of diagnosing, treating and monitoring dogs with suspected epilepsy. With a simple, real life example, veterinary staff can consolidate their knowledge on epilepsy in dogs and understand more about the treatment options available.
Will Peel, product manager at TVM UK explains:
“The addition of Vetbromide to our epilepsy range allows vets more flexibility when treating epileptic patients. To further assist vets, we are also offering a wide range of free literature and in-practice support to ensure that veterinary staff are up to speed on such a common, yet at times complicated, topic.”
To find out more about Vetbromide and access the e-Learning tool and practice support materials please visit the website, or for further information, contact a TVM UK Territory Manager.
